Will AstraZeneca stock hold above GBX12,876 support as sellers control the short-term trend?

Will AstraZeneca stock hold above GBX12,876 support as sellers control the short-term trend?
AstraZeneca drops 2.54% to GBX13,300

AstraZeneca (AZN) stock is trading at GBX13,300, marking a 2.54% drop on the day. The price sits below its key moving averages, reflecting persistence of bearish momentum in the short, medium, and long term.

AZN price prediction
24H -0.25%
GBX 13,406
48H -0.53%
GBX 13,369.19
7D -0.11%
GBX 13,425
1M 12.56%
GBX 15,128
3M 23.74%
GBX 16,630.27
6M 36.76%
GBX 18,379.92
12M 9.54%
GBX 14,721.55
Current price: GBX 13,440 136.00 1.02%
Closed 11/20
Daily range 13350.00 Arrow from to Icon 13538.00
Weekly range 13274.00 Arrow from to Icon 14222.00
Loading...

Highlights

  • The FDA has granted Priority Review to AstraZeneca's sonesitatug vedotin for advanced gastric and esophageal cancers, potentially enabling accelerated U.S. market access.
  • AstraZeneca renewed its partnership with Tempus AI under a $200 million agreement for advanced clinical data analytics through 2031.
  • Shares of AstraZeneca remain under strong selling pressure, trading below key moving averages with momentum indicators signaling a likely move toward the GBX12,876 to GBX13,723 range.

Regulatory milestones and R&D deals countered by ongoing selling pressure

The grant of Priority Review status by the U.S. Food and Drug Administration for AstraZeneca's sonesitatug vedotin (Sone-Ve) targeting advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma represents a significant regulatory milestone that could accelerate future U.S. market access for this cancer therapy, according to Marketscreener. The expedited FDA process heightens the potential for earlier revenue generation from AZN's oncology portfolio, though any impact will be realized only following regulatory approval. Additionally, AstraZeneca has renewed its partnership with Tempus AI through a $200 million master services agreement extending to the end of 2031, as reported by Benzinga, which secures access to advanced clinical data analytics in support of R&D initiatives. Despite these positive developments, price action has remained under broader selling pressure.

AstraZeneca asset chart
AstraZeneca price dynamics. Source: TradingView.

Oversold momentum and resistance cap price amid continued bearish bias

Technically, AZN is trading below the H1 SMA-20 at GBX13,587, H1 SMA-50 at GBX13,819, and the D1 SMA-200 at GBX13,439, with the Ichimoku Kijun at GBX13,606 acting as immediate resistance. Momentum indicators show MACD and ADX with sell signals, while RSI, Stoch RSI, and CCI are all verified in oversold zones, indicating possible exhaustion in selling but not confirming a reversal. Bull/Bear Power remains negative at -150.2, and the Awesome Oscillator also reinforces the prevailing bearish tone. The price is near today's low, reflecting moderate session volatility and ongoing seller dominance.

Downside breakout risk elevated as range-bound volatility prevails

In the short term, AZN is expected to consolidate within the GBX12,876 to GBX13,723 range, representing the typical volatility band relative to current levels. With a 79% probability assigned to a downward move and 21% to an upward move, a breakout below support at GBX12,876 would likely trigger further declines. Conversely, a bullish reversal scenario requires a close above immediate resistance at GBX13,606 to signal renewed buying interest.

Viktoras Karapetjanc, Traders Union expert, sees the recent FDA Priority Review and Tempus AI partnership renewal as strong positives for AstraZeneca's long-term fundamentals. He believes the oncology pipeline momentum is not yet reflected in market sentiment, with price action still under bearish pressure and AZN trading below key technical levels such as the H1 SMA-20 at GBX13,587 and D1 SMA-200 at GBX13,439. Short-term technicals show persistent selling, though oversold signals suggest potential stabilization. Karapetjanc expects consolidation within GBX12,876 to GBX13,723 until buyers regain confidence. "Despite the prevailing downtrend, I remain constructive on AstraZeneca’s prospects as innovation catalysts are building for future upside."

Earlier, analysts noted that AstraZeneca shares were experiencing sustained bearish pressure despite positive corporate developments. The current technical setup reinforces downside risks, making GBX12,876 a critical support level that traders should monitor for the potential of an accelerated decline.

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.